(Q36673566)

English

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer

scientific article published on December 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

phase I clinical trial

0 references

author name string

R Repp

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H H van Ojik

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

T Valerius

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G Groenewegen

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G Wieland

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

C Oetzel

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

B Stockmeyer

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

W Becker

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Eisenhut

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

H Steininger

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Y M Deo

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

G H Blijham

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J R Kalden

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

J G J van de Winkel

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

M Gramatzki

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

1 December 2003

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

British Journal of Cancer

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

89

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2234-2243

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

IgG Fc receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Clinical trials of Herceptin(trastuzumab).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Multiple roles for the major histocompatibility complex class I- related receptor FcRn

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Bispecific antibodies in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

A pilot trial of GM-CSF and MDX-H210 in patients with erbB-2-positive advanced malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

The FcgammaRIa (CD64) ligand binding chain triggers major histocompatibility complex class II antigen presentation independently of its associated FcR gamma-chain.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Natural killer cells and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Human neutrophil Fc gamma receptor distribution and structure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Immune interferon induces the receptor for monomeric IgG1 on human monocytic and myeloid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Neutrophils express the high affinity receptor for IgG (Fc gamma RI, CD64) after in vivo application of recombinant human granulocyte colony-stimulating factor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

30 September 2017

Human monocytes and U937 cells bear two distinct Fc receptors for IgG.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

28 June 2018

Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

28 June 2018

Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

28 June 2018

Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

20 September 2018

Further characterization of the neutrophil oxidative burst by flow cytometry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2395280

20 September 2018

Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6601367

21 January 2018

Three-phase white blood cell scan: diagnostic validity in abdominal inflammatory diseases

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetic-pharmacodynamic relationships of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monoclonal antibody therapies-a 'constant' threat to cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bifunctional NHS-BAT ester for antibody conjugation and stable technetium-99m labeling: conjugation chemistry, immunoreactivity and kit formulation

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules

1 reference

https://pubmed.ncbi.nlm.nih.gov/14676800

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/SJ.BJC.6601367

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36673566&oldid=2199169092"